2DG Archives - Medically Speaking
Home Tags Posts tagged with "2DG"
Tag:

2DG

drug
Uncategorized

Express Pharma Granules India gets licence from DRDO to manufacture and market COVID-19 drug 2-DG

by Medically Speaking Team
written by Medically Speaking Team

Granules India said on Thursday that it has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

“Granules is working closely with DRDO team to launch the product in India at the earliest,” it added.

The drug reduces a patient’s average recovery time by two and half days and oxygen demand by up to 40 per cent, the filing said.

0 comment
0 FacebookTwitterPinterestEmail
drug
Uncategorized

BDR Pharma inks license agreement with DRDO to produce COVID-19 drug 2-DG

by Medically Speaking Team
written by Medically Speaking Team

BDR Pharma on Monday said it has inked a licensing pact with the Defence Research and Development Organisation (DRDO) to manufacture, distribute, and market COVID-19 drug 2-Deoxy-D-Glucose (2-DG) in the country. BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.

Last month, the Drugs Controller General of India (DCGI) had approved the oral medication for emergency usage as adjuvant therapy in mild to severe COVID-19 patients.

“We are pleased to secure a license from the DRDO and add 2-Deoxy-D-Glucose to our COVID product offering. This arrangement aims to ensure that this drug reaches as many eligible Indian patients as possible who are suffering from the devastating pandemic.

0 comment
0 FacebookTwitterPinterestEmail
DRDO
Uncategorized

MSG enters with agreement to mfg, market 2-DG

by Medically Speaking Team
written by Medically Speaking Team

MSN Laboratories has signed a license agreement with the Defence Research and Development Organization (DRDO) for the manufacturing, distribution and marketing of Covid-19 drug 2-DG in India.

MSN said it will be launching the drug under the brand name MSN 2D in sachet form as a twice a day product in strength of 2.24 g.

0 comment
0 FacebookTwitterPinterestEmail
drug
Uncategorized

Mankind Pharma receives making and marketing license for 2-DG from DRDO

by Medically Speaking Team
written by Medically Speaking Team

Mankind Pharma said it has received the licence from the Defence Research and Development Organisation (DRDO) to manufacture and market oral 2-deoxy-D-glucose (2-DG), used for the treatment of COVID-19. 2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior. The clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy’s Laboratories, Mankind Pharma said in a statement. The company will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.

The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said. The drug is found to help the hospitalised COVID-19 patients recover faster and is also known to reduce the supplemental oxygen dependency among the COVID-19 patients, it added.

‘Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic,’ the company said.

0 comment
0 FacebookTwitterPinterestEmail
DRDO
Uncategorized

Laurus Labs gets DRDO nod to make and market 2-Deoxy-D-glucose (2DG) in India

by Medically Speaking Team
written by Medically Speaking Team

Laurus Labs announced that it has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.

Laurus Labs has already applied with CDSCO for emergency use authorization (EUA) for 2DG.

0 comment
0 FacebookTwitterPinterestEmail
Dr Reddy's
Uncategorized

Dr Reddy’s Laboratories announces commercial launch of anti-COVID 2-DG drug

by Medically Speaking Team
written by Medically Speaking Team

Dr Reddy’s Laboratories has announced the commercial launch of 2-Deoxy-D-Glucose (2-DG) used to treat Covid patients, adding that the drug will be available across hospitals in metros and Tier 1 cities in the initial weeks.

The drug, developed by DRDO and Dr Reddy’s Laboratories, has been found to help speed up recovery and reduce oxygen dependence. Dr Reddy’s has launched the drug in the form of sachets.

“Dr Reddy’s will supply to major government as well as private hospitals across India. In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India,” the company said in a statement.

The maximum selling price has been capped at ₹ 990, with a discounted rate offered to government institutions, it said.

“2-DG is an oral drug. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care,” the company added.

The drug was approved for emergency use in COVID-19 patients on May 1.

0 comment
0 FacebookTwitterPinterestEmail
DRDO
Uncategorized

DRDO invites expression of interest for bulk production of Covid drug 2-DG

by Medically Speaking Team
written by Medically Speaking Team

The Defence Research and Development Organisation (DRDO), which developed 2 -Deoxy-D-Glucose (2-DG), a drug used for the treatment of COVID-19 patients, has called for Express of Interest (EOI) to transfer the technology to Indian pharmaceutical industries for production.

The 2-DG is developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’ Laboratories.

The third phase trials of 2-DG began in January, while the phase trials were conducted over three month period between June and September last year and involved 110 patients.

The DCGI had granted permission in May last year to Dr Reddy’s Laboratories for conducting a clinical trial of 2 DG for “acute treatment of moderate to severe Covid-19 patients.”

The government has recently launched 2-DG as an anti -Covid-19 therapeutic application of the drug 2-Deoxy-D-glucose (2-DG).

Patients treated with 2-DG have shown negative RT-PCR in COVID-19 patients.

0 comment
0 FacebookTwitterPinterestEmail
drug
Uncategorized

Guidelines for the use of 2DG med released by DRDO

by Medically Speaking Team
written by Medically Speaking Team

Defence Research and Development Organisation (DRDO) on Tuesday released guidelines on how and when to use its anti-Covid medicine 2-Deoxy-d-glucose (2-DG) medicine. The drug was launched last month by the Ministry of Defence. It has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr Reddy’s Laboratories (DRL) in Hyderabad.

The DRDO said that 2-DG medicine should be used under the supervision of a doctor. The oral drug for emergency use is an adjunct therapy to treat severe Covid patients. It reduces dependence on supplemental oxygen.

Guidelines To Use 2-DG
  1. 2DG should be prescribed early on by the doctors. This drug can be prescribed for up to 10 days and the recipients can be both moderate to severe COVID patients. 
  2. This drug is approved for ‘Emergency Use’, and can be used as an adjunct therapy alongside the standard procedure followed in the treatment of a Covid patient. 
  3. 2DG has not yet been tested on patients with uncontrolled diabetes, severe cardiac problems, ARDS, severe hepatic and renal impairment. Hence, extra caution needs to be maintained.
  4. Lactating and pregnant women should not be prescribed with 2DG, and the same applies to people below the age of 18.
  5. Patients/Attendants looking to procure 2DG medicine should email their requirement to [email protected]. The email ID is of Dr. Reddy’s Lab, Hyderabad.

The drug was cleared by Drugs Controller General of India (DCGI) on May 1 for emergency use as an adjunct therapy in moderate to severe Covid-19 patients. The first batch of the indigenously developed anti-Covid-19 drug was released by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan on May 17.

The price of DRDO’s 2DG anti-COVID 19 drug has been fixed at Rs 990 per sachet by pharma major Dr Reddy’s Laboratories. However, the drug will be provided by government hospitals at a discounted price. According to Dr Reddy’s Laboratories, the drug will be commercially launched in mid-June.

0 comment
0 FacebookTwitterPinterestEmail
DRDO
Uncategorized

DRDO’s 2-DG priced at Rs. 990 per sachet

by Medically Speaking Team
written by Medically Speaking Team

DRDO’s (Defence Research and Development Organization) anti-Covid drug has been priced at Rs 990 per sachet by Dr Reddy’s Laboratories (DRL), officials said on Friday. The Hyderabad-based pharma company, however, will provide the medicine to Centre and state government at a discounted price.

The first batch of DRDO’s anti-Covid drug was released on May 17 by Defence Minister Rajnath Singh and health minister Dr Harsh Vardhan, after the Drugs Controller General of India permitted the emergency use authorization of 2-deoxy-D-glucose (2-DG), anti-viral drug as an adjunct therapy for moderate to severe coronavirus patients.

0 comment
0 FacebookTwitterPinterestEmail
Dr Reddy's
Uncategorized

Dr Reddy’s releases crucial information regarding 2DG drug

by Medically Speaking Team
written by Medically Speaking Team

Dr Reddy’s, on Wednesday released an important information regarding 2-Deoxy-D-glucose, a drug developed by INMAS, a DRDO lab in collaboration with Dr Reddy’s, for the treatment of Covid-19.

  • Emergency use approval has been granted in India for anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2DG) developed by INMAS, a lab of the DRDO, in collaboration with Dr Reddy’s laboratories.
  • 2DG is an oral anti-viral drug that can be administered only upon prescription to hospitalised moderate to severe Covid-19 patients as adjunct (add on) therapy along with existing standard of care.
  • 2DG has not yet been launched into the market. Price per sachet has not yet been announced.
  • Commercial launch and supply of 2DG to major Government and private hospitals is expected to commence in mid-June. Price is being determined with a view to making it accessible and affordable to as many patients as possible, and will be announce soon.
  • Please beware of agents selling spurious or illegal products in the name of 2DG.
  • Please beware of unverified messages relating to 2DG circulating on Social media and Whatsapp.
0 comment
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts
What Happens When You Lack Vitamin A In Your Body? 5 Signs to Watch Out For Why Breast Cancer Screening at 40 is a Life-Saving Choice Avoid These Food and Medicine Combos Identifying Rheumatoid Arthritis: Early Signs and Symptoms to Watch For “Delicious Diabetes-Friendly Smoothies: 5 Homemade Recipes to Satisfy Your Sweet Tooth Without Spiking Blood Sugar”